CUE vs VMC · rev $9.3M vs P/E 35, rev $7.42B
Cue Biopharma (CUE) versus Vulcan Materials Company (VMC) — a side-by-side from cached financials, not a winner call.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Vulcan Materials Company (VMC) is a building materials company listed on NYSE.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
Latest reported VMC revenue for 2024-12-31 was $7.42B. Net income was $913.1M. Revenue was down 4.7% from 2023-12-31 to 2024-12-31. VMC currently screens at market cap $38.25B and trailing P/E 34.9.
CUE currently screens at market cap $59.5M. VMC currently screens at market cap $38.25B and trailing P/E 34.9.
Not investment advice. Open the CUE and VMC stock pages for the full models.
Not investment advice.